Tenecteplase thrombolysis for stroke up to 24 hours after onset with perfusion imaging selection: the umbrella phase IIa CHABLIS-T randomised clinical trial

Xin Cheng, Lan Hong, Leonid Churilov, Longting Lin, Yifeng Ling, Jin Zhang, Jianhong Yang, Yu Geng, Danhong Wu, Xueyuan Liu, Xiaoyu Zhou, Yuwu Zhao, Qijin Zhai, Liandong Zhao, Yangmei Chen, Ying Guo, Xiaofei Yu, Fan Gong, Yi Sui, Gang Li, Lumeng Yang, Hong-Qiu Gu, Yilong Wang, Mark Parsons, Qiang Dong, the CHABLIS-T collaborators

ABSTRACT

Background The performance of intravenous tenecteplase in patients who had an acute ischaemic stroke with large/medium vessel occlusion or severe stenosis in an extended time window remains unknown. We investigated the promise of efficacy and safety of different doses of tenecteplase manufactured in China, in patients who had an acute ischaemic stroke with large/medium vessel occlusion beyond 4.5-hour time window.

Methods The Chinese Acute Tissue-Based Imaging selection for Lysis In Stroke-Tenecteplase was an investigator-initiated, umbrella phase IIa, open-label, blinded-endpoint, Simon’s two-stage randomised clinical trial in 13 centres across mainland China. Participants who had salvageable brain tissue on automated perfusion imaging and presented within 4.5–24 hours from time of last seen well were randomised to receive 0.25 mg/kg tenecteplase or 0.32 mg/kg tenecteplase, both with a bolus infusion over 5–10 s. The primary outcome was proportion of patients with promise of efficacy and safety defined as reaching major reperfusion without symptomatic intracranial haemorrhage at 24–48 hours after thrombolysis. Assessors were blinded to treatment allocation. All participants who received tenecteplase were included in the analysis.

Results A total of 86 patients who had an acute ischaemic stroke identified with anterior large/medium vessel occlusion or severe stenosis were included in this study from November 2019 to December 2021. All of the 86 patients enrolled either received 0.25 mg/kg (n=43) or 0.32 mg/kg (n=43) tenecteplase, and were available for primary outcome analysis. Fourteen out of 43 patients in the 0.25 mg/kg tenecteplase group and 10 out of 43 patients in the 0.32 mg/kg tenecteplase group reached the primary outcome, providing promise of efficacy and safety for both doses based on Simon’s two-stage design.

Discussion Among patients with anterior large/medium vessel occlusion and significant penumbral mismatch presented within 4.5–24 hours from time of last seen well, tenecteplase 0.25 mg/kg and 0.32 mg/kg both provided sufficient promise of efficacy and safety.

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ Tenecteplase has now been proven to be non-inferior to alteplase, in patients who had an acute ischaemic stroke within the 4.5-hour time window. However, its performance in patients who had an acute stroke with large/medium vessel occlusion or severe stenosis in an extended time window remains unknown.

WHAT THIS STUDY ADDS

⇒ Among patients with anterior large/medium vessel occlusion and significant penumbral mismatch presented within 4.5–24 hours from time of last seen well, tenecteplase 0.25 mg/kg and 0.32 mg/kg both provided sufficient promise of efficacy and safety.

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ It seems feasible to extend the time window of intravenous tenecteplase thrombolysis to 24 hours after last seen well through perfusion imaging selection.


INTRODUCTION

Thrombolysis with alteplase is limited by its short half-life and low recanalisation rate of large vessel occlusion. Tenecteplase—a genetically modified variant of alteplase—has gained increasing interest as an alternative for alteplase over the past decade. This is mainly due to its practical advantages (single bolus, rather than 1-hour infusion) and a number of hypothetical advantages over alteplase, including greater fibrin specificity. It has been demonstrated that tenecteplase is non-inferior to alteplase in unselected patients who had an ischaemic stroke, ...
and may be superior to alteplase in acute large vessel occlusion. Prior tenecteplase trials have recruited acute ischaemic stroke presenting no longer than 6 hours from symptom onset. Thus, the evidence of performance of tenecteplase beyond 4.5 hours for thrombolysis, though increasing evidence suggests the optimal dose of tenecteplase in acute stroke of the Western population is 0.25 mg/kg and the Tenecteplase in Stroke Patients Between 4.5 and 24 Hours (TIMELESS, NCT03785678) trial has reported that 0.25 mg/kg tenecteplase could improve recanalisation compared with placebo. The appropriate dose in the Chinese patients with acute large/medium vessel occlusion or severe stenosis was unknown when the trial started.

Therefore, our hypothesis is that tenecteplase administered to patients who had an ischaemic stroke with a favourable penumbral profile on perfusion CT (CTP) between 4.5 and 24 hours from time of last seen well would be safe and beneficial.

We conducted the CHinese Acute tissue-Based imaging selection for Lysis In Stroke-Tenecteplase (CHABLIS-T) umbrella phase IIa randomised clinical trial. The goal of CHABLIS-T was to investigate the promise of efficacy and safety of various doses of tenecteplase in Chinese patients who had an acute ischaemic stroke with large/medium vessel occlusion or severe stenosis in the anterior circulation and a favourable penumbral profile between 4.5 and 24 hours from time of last seen well. The tenecteplase used in the trial was produced and approved for treating acute myocardial infarction in China and has been used in Tenecteplase Reperfusion therapy in Acute ischaemic Cerebrovascular Events (TRACE) trials, which had the same terminal amino acid sequence and different production process to the tenecteplase made by Boehringer (Metalyse) and Genentech (TNKase).

METHODS

Study design

When the trial started, the appropriate dose of tenecteplase in acute stroke, especially in Asian population, was unknown. Moreover, the bioequivalence of tenecteplase produced in China was also unclear. The CHABLIS-T trial adopted a Simon’s two-stage design for individual dose stratum. The purpose of Simon’s two-stage design is to determine whether tenecteplase has sufficient promise against acute stroke with large/medium vessel occlusion or severe stenosis in an extended time window in Chinese patients to warrant further investigation. Under this design, a small group of patients were enrolled in the first stage, and the activation of the second stage depended on a prespecified number of positive responses observed from the first stage. The trial was conducted in 13 centres across mainland China from November 2019 to December 2021.

The protocol and statistical analysis plan are provided in online supplemental file.

Participants

Eligible patients were considered eligible if they (1) presented with acute ischaemic stroke within 4.5–24 hours from time of last seen well and were aged 18 years or older; (2) had a clinically significant acute neurological deficit measured by the baseline National Institutes of Health Stroke Scale (NIHSS) score; (3) had a prestroke modified Rankin Scale (mRS) 0–2; (4) fulfilled the ‘dual target’ imaging criteria, on baseline multimodal CT imaging. Participants were identified with anterior circulation large/medium vessel occlusion or severe stenosis (defined as more than 70% narrowing compared with the adjacent vessel calibre), including the extracranial or intracranial internal carotid artery (ICA-IC/EC), first or second segment of the middle cerebral artery (MCA-M1/M2), and first or second segment of the anterior cerebral artery (ACA-A1/A2) on CT angiography. Additionally, a favourable penumbral profile was required on CTP imaging using automated real-time perfusion volumetric software, AutoMIStar (Apollo Medical Imaging Technology, Melbourne, Victoria, Australia). A favourable penumbral profile was a hypoperfusion lesion volume (delay time >3s) to infarct core volume (relative cerebral blood flow <30%) ratio that was greater than 1.2 with an absolute difference of volume greater than 10 mL, and an ischaemic core volume less than 70 mL.

Detailed inclusion and exclusion criteria are listed in online supplemental file.

Randomisation, intervention and blinding

Eligible patients were enrolled and randomly assigned in a 1:1 ratio to either dose stratum (0.25 mg/kg, maximum 25 mg; and 0.32 mg/kg, maximum 40 mg) of tenecteplase (Guangzhou Recomgen Biotech Co), as a bolus over 5–10s and a following 2 mL bolus of saline for injection. Randomisation was performed using permuted blocks through a centralised website by local stroke neurologists. Patients were stratified according to time from last seen well (4.5–12 hours, 12–24 hours) and site of occlusion or severe stenosis (ICA-IC and MCA-M1; ICA-EC, MCA-M2 and ACA). The dosage of tenecteplase was open label to the patients and the clinicians involved in the treatment of participants. Bridging endovascular treatment was performed according to local guidelines. Guideline-based intensive care for patients who had an acute ischaemic stroke with intravenous thrombolysis was recommended for every patient. The investigators involved in the subsequent radiological and clinical evaluation were blinded to the allocation.

Outcomes

The primary outcome was a binary composite of efficacy and safety, that is, presence of major reperfusion at the initial catheter angiography or repeated CTP 4–6 hours in the absence of symptomatic intracerebral
haemorrhage (sICH) at 24–48 hours after intravenous tenecteplase. Major reperfusion was defined as the restoration of blood flow of greater than 50% of the involved territory. For patients not transferred to the catheter laboratory after thrombolysis, major reperfusion was considered as the hypoperfusion lesion volume (delay time >3s) of the repeated CTP 4–6 hours decreased to less than 50% of the hypoperfusion lesion volume of the baseline CTP. For patients transferred to the catheter laboratory, major reperfusion was evaluated as a modified Treatment In Cerebral Ischemia (mTICI) score 2b/3 at the initial catheter angiography. SICH was defined according to the European Co-operative Acute Stroke Study-II criteria. The secondary radiological efficacy outcomes included recanalisation and infarct growth. The secondary clinical efficacy outcomes included mRS 0–1, mRS 0–2 and mRS distribution at 90 days, major neurological improvement at 24–48 hours and change in the NIHSS score within 24–48 hours. The secondary radiological safety outcomes included parenchymal haematoma type 2 (PH2), sICH and any ICH at 24–48 hours post-treatment. The secondary clinical safety outcomes included mRS 5–6 at 90 days and systemic bleeding. Additionally, Barthel Index at 90 days was also collected. The details of the secondary outcomes can be found in online supplemental file.

The imaging protocol of multimodal CT at each centre was centrally standardised through careful quality control. All of the imaging results were centrally analysed in a core laboratory. Baseline multimodal CT imaging was reanalysed to make sure that the entry criteria were met. The radiological outcome measurements were evaluated by two independent neuroradiologists, and a third independent rater was consulted in cases of disagreement.

Sample size calculations

The sample size was calculated based on the results derived from the Tenecteplase vs Alteplase before Endo-vascular Therapy for Ischemic Stroke (EXTEND-IA TNK) trial, where 22% of patients in the intravenous tenecteplase group and 10% of patients in the intravenous alteplase group reached major reperfusion, and 1% of patients, respectively, in both groups were found to have sICH. To adopt a conservative approach, for each dose stratum within the umbrella design, the null hypothesis was that not more than 10% of patients would achieve a positive primary outcome following the respective dose of tenecteplase, while the alternative hypothesis was that, not less than 25% of patients would achieve a positive primary outcome following the respective dose of tenecteplase. Sample size estimation using Simon’s two-stage design was conducted for each dose stratum, according to which the null hypothesis that the true response rate was 10% was tested against a one-sided alternative. In the first stage, 18 patients were to be accrued. If there were two or fewer positive responses in these 18 patients, the dose stratum was to be stopped. Otherwise, 25 additional patients were to be accrued for a total of 43 patients for each dose stratum. The null hypothesis for each stratum was to be rejected if eight or more positive responses were observed in 43 patients. This design was to yield a type I error rate of 0.05 and a power of 0.8 when the true response rate was 25%. Overall, at least 36 patients were to be enrolled with a maximum enrolment of 86 patients equally distributed between the two dose strata (figure 1).

Statistical analysis

All participants receiving tenecteplase were included in the analysis. For the analysis of the primary endpoint, as described above, if 8 or more out of the 43 patients reached the primary endpoint within a given stratum, the respective tenecteplase dose could be considered of being sufficient promise in terms of efficacy and safety and as a qualified candidate dose for the subsequent phase IIb trial.

Since the design of this study did not aim to compare the safety and efficacy of the two tenecteplase doses within the umbrella design, the analyses of secondary outcomes were descriptive. Secondary outcomes were described using percentages, mean with standard deviation (SD) and median with interquartile range (IQR as appropriate. Normality was tested using Shapiro-Wilk test.

In order to inform the design and planning for the subsequent phase IIb trial, we also estimated the proportions of participants achieving primary and secondary outcomes in patients without severe stenosis in the two tenecteplase dose strata.

No missing data for baseline information and primary outcome analysis were observed. Although 13.95% of participants had missing data on Barthel Index, its influence was considered to be minimal since it is a secondary outcome and the analyses did not involve a comparison between tenecteplase dose strata.

The statistical analysis was performed on STATA V.15.1 (StataCorp, College Station, Texas, USA). A data safety monitoring board oversaw the enrolment of the total 86 patients in this trial.

RESULTS

From 27 November 2019 to 30 September 2021, a total of 2193 patients who had an acute ischaemic stroke presented within 4.5–24 hours from time of last seen well at 13 sites, where 86 patients were randomised and received tenecteplase treatment in this trial. The flow diagram of patient selection is shown in figure 2. The preplanned interim analysis according to Simon’s two-stage design was conducted in December 2020, demonstrating that each tenecteplase dose stratum had three or more patients reaching the primary endpoint, enabling...
progression to stage 2 in both dose strata. Forty-three
patients were assigned to each 0.25 mg/kg tenecteplase
and 0.32 mg/kg tenecteplase strata, and received corre-
sponding tenecteplase treatment as allocated. The base-
line demographic, clinical and imaging characteristics of
the two tenecteplase dose strata are listed in table 1.

All of the 86 patients were available for the primary
outcome analysis. The primary outcome analysis showed
that 14 out of 43 (32.6%, 95% CI 20.2% to 48.0%) patients in the 0.25 mg/kg tenecteplase stratum and 10
out of 43 (23.3%, 95% CI 12.9% to 38.3%) patients in the
0.32 mg/kg tenecteplase stratum reached major reper-
fusion without sICH after tenecteplase thrombolysis. Addi-
tionally, regardless of the occurrence of haemorrhagic
events, the numbers of patients achieving major reper-
fusion were 15 (34.9%, 95% CI 22.1% to 50.3%) and 12
(27.9%, 95% CI 16.5% to 43.2%) in the 0.25 mg/kg and
0.32 mg/kg dose strata, respectively.

Prespecified secondary efficacy and safety outcomes
are presented in table 2. Recanalisation was attained in
18 (43.9%, 95% CI 29.5% to 59.4%) patients in both
tenecteplase dose strata (with 41 patients available for
analysis each arm) post-thrombolysis. Excellent func-
tional outcome (mRS 0–1) was achieved in 12 (27.9%,
95% CI 16.5% to 43.2%) patients in the 0.25 mg/kg
tenecteplase stratum and in 21 (48.8%, 95% CI 34.2% to
63.6%) patients in the 0.32 mg/kg tenecteplase stratum
at 90 days. sICH occurred in 4 (9.3%, 95% CI 3.5% to
22.6%) patients in the 0.25 mg/kg tenecteplase stratum
and in 4 (9.3%, 95% CI 3.5% to 22.6%) in the 0.32 mg/
kg tenecteplase stratum. Details of severe adverse events
are displayed in online supplemental table 1.

When excluding 13 patients with severe arterial
stenosis, the baseline characteristics of the 73 patients
with complete artery occlusion are listed in online supple-
mental table 2. The primary outcome was still achieved in
9 out of 35 (25.7%, 95% CI 13.8% to 42.8%) patients in
the 0.25 mg/kg tenecteplase stratum and in 9 out of 38
(23.7%, 95% CI 12.7% to 39.9%) patients in the 0.32 mg/
kg tenecteplase stratum. Secondary outcomes in patients
with complete artery occlusion of two tenecteplase dose
strata are shown in online supplemental table 3. Addi-
tionally, the baseline characteristics of the 52 patients
without bridging endovascular treatment were listed in
online supplemental table 4.

**DISCUSSION**

In this randomised trial, among 86 patients recruited, 14
out of 43 patients in the 0.25 mg/kg dose stratum and
10 out of 43 patients in the 0.32 mg/kg dose stratum
achieved major reperfusion without occurrence of sICH,
both surpassing the predefined eight-patient threshold
of reaching the primary outcome. Therefore, both
tenecteplase 0.25 mg/kg and tenecteplase 0.32 mg/kg demonstrated sufficient promise of efficacy and safety. CHABLIS-T is also one of the few trials that reported the performance of tenecteplase thrombolysis in the extended time window.

In TRACE Study, three doses of 0.1, 0.25, 0.32 mg/kg tenecteplase were compared with 0.9 mg/kg alteplase in Chinese patients with acute ischaemic stroke within 3 hours from symptom onset, which showed similar safety profiles. However, in another phase IIb trial, two doses of 0.1 and 0.25 mg/kg tenecteplase were compared with alteplase, which showed the higher dose of tenecteplase was superior to the lower dose and to alteplase for all efficacy outcomes. Therefore, we abandoned the lower dose of 0.1 mg/kg tenecteplase, and examined the promise of efficacy and safety in the other higher doses of tenecteplase, that is, 0.25 mg/kg and 0.32 mg/kg.

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Baseline characteristics of the patients randomised</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Tenecteplase 0.25 mg/kg (n=43)</td>
</tr>
<tr>
<td>Age, years</td>
<td>68.3 (13.1)</td>
</tr>
<tr>
<td>Male sex</td>
<td>25 (58.1%)</td>
</tr>
<tr>
<td>NIHSS score at randomisation</td>
<td>11 (8–15)</td>
</tr>
<tr>
<td>Stroke aetiology</td>
<td></td>
</tr>
<tr>
<td>Cardioembolism</td>
<td>15 (34.9%)</td>
</tr>
<tr>
<td>Large artery atherosclerosis</td>
<td>20 (46.5%)</td>
</tr>
<tr>
<td>Undetermined aetiology</td>
<td>8 (18.6%)</td>
</tr>
<tr>
<td>Medical history</td>
<td></td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>14 (32.6%)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>27 (62.8%)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>12 (27.9%)</td>
</tr>
<tr>
<td>Smoking</td>
<td>15 (34.9%)</td>
</tr>
<tr>
<td>Ischaemic stroke or transient ischaemic attack</td>
<td>6 (14.0%)</td>
</tr>
<tr>
<td>TLSW to randomisation</td>
<td></td>
</tr>
<tr>
<td>4.5–12 hours</td>
<td>25 (58.1%)</td>
</tr>
<tr>
<td>12–24 hours</td>
<td>18 (41.9%)</td>
</tr>
<tr>
<td>Witnessed stroke</td>
<td>21 (48.8%)</td>
</tr>
<tr>
<td>Transferred to catheter lab</td>
<td>17 (39.5%)</td>
</tr>
<tr>
<td>Underwent endovascular treatment</td>
<td>17 (39.5%)</td>
</tr>
<tr>
<td>TLSW to hospital arrival, min</td>
<td>497 (310–815)</td>
</tr>
<tr>
<td>TLSW to initiation of intravenous therapy, min</td>
<td>645 (481–973)</td>
</tr>
<tr>
<td>Time from hospital arrival to initiation of intravenous therapy, min</td>
<td>130 (99–159)</td>
</tr>
<tr>
<td>Time from initiation of intravenous thrombolysis to initial angiographic assessment, min*</td>
<td>69.0 (45.0–94.5)</td>
</tr>
<tr>
<td>Site of artery occlusion or severe stenosis</td>
<td></td>
</tr>
<tr>
<td>Extracranial segment of intracranial carotid artery</td>
<td>3 (7.0%)</td>
</tr>
<tr>
<td>Intracranial segment of intracranial carotid artery</td>
<td>3 (7.0%)</td>
</tr>
<tr>
<td>First segment of middle cerebral artery</td>
<td>25 (58.1%)</td>
</tr>
<tr>
<td>Second segment of middle cerebral artery</td>
<td>9 (20.9%)</td>
</tr>
<tr>
<td>Anterior cerebral artery</td>
<td>3 (7.0%)</td>
</tr>
<tr>
<td>Tandem occlusion</td>
<td>0 (0.0%)</td>
</tr>
<tr>
<td>Vessel severe stenosis at baseline</td>
<td>8 (18.6%)</td>
</tr>
<tr>
<td>Hypoperfusion lesion volume at baseline, mL</td>
<td>77 (50–114)</td>
</tr>
<tr>
<td>Ischaemic core volume at baseline, mL</td>
<td>8 (4–15)</td>
</tr>
</tbody>
</table>

Data are mean (SD), n (%), median (IQR).

*Tenecteplase 0.25 mg/kg: n=17; tenecteplase 0.32 mg/kg: n=18.
IQR, interquartile range; NIHSS, National Institutes of Health Stroke Scale; SD, standard deviation; TLSW, time from last seen well.
Prompt reperfusion is of great importance for patients who had an acute ischaemic stroke with large vessel occlusion. Previous studies have shown that tenecteplase, as a single bolus administration, could achieve more rapid and substantial reperfusion compared with alteplase.21–23 The recently reported TIMELESS trial (NCT03785678) has also reported a higher rate of recanalisation at 24 hours in the tenecteplase group than the placebo group.17 The current trial showed that both 0.25 mg/kg and 0.32 mg/kg tenecteplase dose groups could reach a substantial reperfusion rate of around 30%, compared with the 20% in the EXTEND-IA TNK trials. One possible explanation is that we included medium vessel occlusion or severe stenosis, which could have higher reperfusion rate treated by tenecteplase. Another possible explanation is that the time window of reperfusion assessment in CHABLIS-T was around 60 min for patients transferred for catheter angiography (similar to EXTEND-IA TNK), and 4–6 hours for patients not transferred (60% of CHABLIS-T participants).7,8 Apart from the time window, the imaging modality of reperfusion assessments may also play a part, since reperfusion status was mainly assessed through repeated perfusion imaging rather than catheter angiography in the CHABLIS-T trial, which was the opposite to the EXTEND-IA TNK trials.7,8 However, reperfusion status assessed through perfusion imaging has been proven to have at least equivalent predictive ability for functional outcome compared with mTICI scores in catheter angiography.24,25 As for the safety concerns, we did not observe a higher rate of...

<table>
<thead>
<tr>
<th>Table 2 Primary and secondary efficacy and safety outcomes</th>
<th>Tenecteplase 0.25 mg/kg (n=43)</th>
<th>Tenecteplase 0.32 mg/kg (n=43)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Primary outcome</strong> (major reperfusion without the occurrence of symptomatic ICH)</td>
<td>14 (32.6%)</td>
<td>10 (23.3%)</td>
</tr>
<tr>
<td><strong>Secondary outcome</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Efficacy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recanalisation†</td>
<td>18 (43.9%)</td>
<td>18 (43.9%)</td>
</tr>
<tr>
<td>Infarct growth at 3–5 days, mL‡</td>
<td>23.9 (3.5–55.3)</td>
<td>16.9 (6.7–81.0)</td>
</tr>
<tr>
<td>Major neurological improvement at 24–48 hours§</td>
<td>7 (17.1%)</td>
<td>8 (18.6%)</td>
</tr>
<tr>
<td>Change in NIHSS score at 24–48 hours compared with baseline§</td>
<td>−1.0 (−6.5, 2.0)</td>
<td>0.0 (−3.0, 2.0)</td>
</tr>
<tr>
<td>mRS score 0–1 at 90 days</td>
<td>12 (27.9%)</td>
<td>21 (48.8%)</td>
</tr>
<tr>
<td>mRS score 0–2 at 90 days</td>
<td>20 (46.5%)</td>
<td>26 (60.5%)</td>
</tr>
<tr>
<td>mRS score at 90 days</td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>7 (16.3%)</td>
<td>8 (18.6%)</td>
</tr>
<tr>
<td>1</td>
<td>5 (11.6%)</td>
<td>13 (30.2%)</td>
</tr>
<tr>
<td>2</td>
<td>8 (18.6%)</td>
<td>5 (11.6%)</td>
</tr>
<tr>
<td>3</td>
<td>5 (11.6%)</td>
<td>3 (7.0%)</td>
</tr>
<tr>
<td>4</td>
<td>7 (16.3%)</td>
<td>7 (16.3%)</td>
</tr>
<tr>
<td>5</td>
<td>5 (11.6%)</td>
<td>5 (11.6%)</td>
</tr>
<tr>
<td>6</td>
<td>6 (14.0%)</td>
<td>2 (4.7%)</td>
</tr>
<tr>
<td><strong>Safety</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Symptomatic ICH</td>
<td>4 (9.3%)</td>
<td>4 (9.3%)</td>
</tr>
<tr>
<td>Any ICH</td>
<td>21 (48.8%)</td>
<td>13 (30.2%)</td>
</tr>
<tr>
<td>Parenchymal haematoma type 2</td>
<td>5 (11.6%)</td>
<td>1 (2.3%)</td>
</tr>
<tr>
<td>mRS score 5–6 at 90 days</td>
<td>11 (25.6%)</td>
<td>7 (16.3%)</td>
</tr>
<tr>
<td>Systematic haemorrhage</td>
<td>3 (7.0%)</td>
<td>1 (2.3%)</td>
</tr>
<tr>
<td>Barthel Index at 90 days¶</td>
<td>95.0 (50.0–100.0)</td>
<td>95.0 (47.5–100.0)</td>
</tr>
</tbody>
</table>

Data are n (%), median (IQR).

*Major reperfusion was assessed at the initial catheter angiography or repeated CTP 4–6 hours and symptomatic ICH was assessed at 24–48 hours after intravenous tenecteplase treatment.
†Tenecteplase 0.25 mg/kg: n=41; tenecteplase 0.32 mg/kg: n=41.
‡Tenecteplase 0.25 mg/kg: n=36; tenecteplase 0.32 mg/kg: n=41.
§Tenecteplase 0.25 mg/kg: n=41.
¶Tenecteplase 0.25 mg/kg: n=33; tenecteplase 0.32 mg/kg: n=41.
CTP, perfusion CT; ICH, intracranial haemorrhage; IQR, interquartile range; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale.
sICH or PH2 in the higher dose stratum. However, the percentages of haemorrhagic transformation (including symptomatic and asymptomatic) in this trial were notably higher than those of randomised controlled trials with patients with large vessel occlusion treated with intravenous thrombolysis. Since the thrombolytic time windows of prior trials range from ≤4.5 hours to ≤9 hours after last seen well, the higher risk of haemorrhagic transformation in this trial can be partly explained by the longer onset-to-reperfusion time. Additionally, though patients in CHABLIS-T have been selected with benign perfusion profiles, they may exhibit risk factors of sICH that could not be detected simply by automatically post-processed perfusion imaging (ie, larger volumes of very low cerebral blood flow), which should be further explored by post-hoc analysis. Despite the higher sICH rates, both doses of 0.25 mg/kg and 0.32 mg/kg tenecteplase appear to be of sufficient promise in patients who had an acute ischaemic stroke with large/medium vessel occlusion or severe stenosis in the extended time window. Though the design of the study was not driven by the direct comparison between 0.25 mg/kg and 0.32 mg/kg tenecteplase, more patients in the 0.25 mg/kg tenecteplase dose stratum reached the primary outcome but failed to achieve 3-month mRS 0–1 or 0–2, compared with patients in the 0.32 mg/kg dose stratum. This discrepancy may be explained by the higher baseline NIHSS, higher prevalence of cardioembolic stroke and higher rate of PH2 in the 0.25 mg/kg dose stratum.

In the CHABLIS-T trial, we included both patients with complete large/medium vessel occlusion as well as those with severe stenosis. The reason why patients with severe stenosis were also eligible for this trial is that a considerable number of acute ischaemic stroke events in East Asian population are due to acute in-situ thrombosis with underlying chronic stenosis resulting from intracranial large artery atherosclerosis. Such patients were also candidates for acute reperfusion therapy and as such excluding patients with severe stenosis would undermine the generalisability of this trial. Notably, when excluding patients with severe stenosis, the primary outcome was still achieved in more than seven patients of each dose stratum in patients with complete artery occlusion.

A novel feature of CHABLIS-T trial was using the umbrella Simon’s two-stage trial design in order to investigate the clinical promise of two doses of tenecteplase. Though not ever applied in stroke previously, Simon’s two-stage design is acknowledged as a simple and effective dose selection method allowing modest sample size, especially in oncology trials.

The study has the following limitations. First of all, the study design did not have an alteplase control group. However, the novel design (for a stroke trial) was aimed for dose finding rather than treatment comparison. Second, the design of this trial does not enable a direct comparison between 0.25 mg/kg and 0.32 mg/kg tenecteplase. With both dose strata reaching the predefined threshold for the primary outcome, both doses can be considered to be of sufficient promise. These results are in accordance with those of EXTEND-IA TNK Part2 trial, where 0.4 mg/kg tenecteplase had similar effect on reperfusion and other outcomes in patients with large vessel occlusions, compared with 0.25 mg/kg tenecteplase. Third, the sample size of this study was underpowered to make reliable conclusions regarding the effect of tenecteplase on long-term functional outcomes (mRS at 90 days). Further, the primary outcome in this dose-finding study was different from that of phase III trials, making direct comparisons unreliable. However, the imaging composite primary outcome of both efficacy and safety is objective, immediate and straightforward, and more suitable for an adaptive sample size re-estimation early phase II design. Moreover, reperfusion without sICH usually translates to a good functional outcome at 90 days. Fourth, the tenecteplase used in the trial is manufactured locally, which limits its generalisability to other countries.

In conclusion, among patients with large/medium vessel occlusion or severe stenosis in the anterior circulation and a favourable penumbral profile presenting within 4.5–24 hours from time of last seen well, both tenecteplase 0.25 mg/kg and 0.32 mg/kg doses demonstrated sufficient promise to achieve substantial reperfusion without sICH. Currently, other tenecteplase-related thrombolytic randomised controlled trials in patients with large vessel occlusion, including TIMELESS (NCT03785678), Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients With Large Vessel Occlusion (ETERNAL-LVO, NCT04454788) and TRACE III (NCT05141305), choose 0.25 mg/kg as the experimental tenecteplase dosage. Additionally, Tenecteplase vs alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2) trial failed to demonstrate superiority of 0.40 mg/kg tenecteplase compared with alteplase with a higher risk of bleeding events and worse functional outcomes in moderate and severe stroke. Based on the results of CHABLIS-T, TRACE and other completed tenecteplase-related randomised controlled trials, a subsequent phase IIIb trial, CHinese Acute tissue In Stroke-Tenecteplase II (CHABLIS-T II) trial, is ongoing to investigate the performance of tenecteplase 0.25 mg/kg in comparison with best medical treatment (NCT04516993). The recent reported TIMELESS trial did not show superiority of tenecteplase in improvement of 3-month outcome though recanalisation rate was improved, which is probably due to the strong clinical benefit of endovascular treatment. Therefore, CHABLIS-T II, together with other ongoing
trials, may help to further explore the optimal clinical setting where the recanalisation benefit of tenecteplase can be maximally translated into clinical benefit.

Author affiliations
1Department of Neurology, National Center for Neurological Disorders, National Clinical Research Centre for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China
2Melbourne Medical School, The Royal Melbourne Hospital, University of Melbourne, Parkville, Victoria, Australia
3University of New South Wales South Western Sydney Clinical School, Ingham Institute for Applied Medical Research, Department of Neurology, Liverpool Hospital, Sydney, New South Wales, Australia
4Department of Neurology, the First Hospital of Shannan Medical University, Taiyuan, China
5Department of Neurology, Ningbo First Hospital, Ningbo, China
6Center for Rehabilitation Medicine, Department of Neurology, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, China
7Department of Neurology, Shanghai First People’s Hospital, Fudan University, Shanghai, China
8Department of Neurology, Shanghai Tenth People’s Hospital, Tongji University, Shanghai, China
9Department of Neurology, Shanghai Sixth People’s Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China
10Department of Neurology, Xuzhou Medical University Affiliated Hospital of Huaiian, Huaiian, China
11Department of Neurology, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China
12Department of Neurology, Pu’er People’s Hospital, Pu’er, China
13Department of Neurology, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, China
14Department of Neurology, Shenyang First People’s Hospital, Shenyang Medical College Affiliated Brain Hospital, Shenyang, China
15Department of Neurology, Shanghai East Hospital, Tongji University, Shanghai, China
16China National Clinical Research Center for Neurological Diseases, Beijing Tian tan Hospital, Beijing, China
17Department of Neurology, Beijing Tian tan Hospital, Capital Medical University, Beijing, China

Twitter Hong-Qiu Gu @hqgu and Yilong Wang @yilong

Acknowledgements We thank all the collaborators, patients and their relatives.

Collaborators The CHABLIS-T collaborators are listed in online supplemental file 1.

Contributors XC and DQ take full responsibility for the work and the conduct of the study, have access to the data, and control the decision to publish. XC, GD, YW and MP conceptualised the study. XC, LH, LL, YL, LY, YW, GD and MP curated and verified the data. LH, LC and H-QG did the formal analyses. XC and GD acquired funding. XC, LH, LL, LC and MP wrote the methods. XC, LH, LL, YL, LY, YW, MP and QG conducted project administration. XC, LH, LL, YL, LZ, YG, DS, DW, XL, XZ, YS, QG and GD recruited patients. XC, LH, LL, MP and GD wrote the article. XC, LH, LC, H-QG, MP and GD had full access to study data. XC and GD take final responsibility for the submitted publication.

Funding This work was supported by the National Key R&D Program of China (2017YFC1308201), Clinical Research Plan of SHDC (SHDC2020CR1041B) and Shanghai Municipal Key Clinical Specialty (shlszdckz06102). Guangzhou Recomgen Biotech Co supplied the investigational product and the insurance for this trial.

Disclaimer Guangzhou Recomgen Biotech Co has no role in trial design, execution and management.

Competing interests XC reported grant support from the National Natural Science Foundation of China and Science and Technology Commission of Shanghai Municipality. YS reported honoraria from Boehringer Ingelheim (China) Investment Co. The other authors report no competing interests.

Patient consent for publication Obtained.

Ethics approval This study involves human participants and was approved by the Ethics Committee of Huashan Hospital, Fudan University (2019(474)). Written informed consent was acquired from all the eligible patients or their legal proxies before randomisation.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available on reasonable request. Readers should contact the corresponding author (at qiang_dong163@163.com) if they wish to enquire about data sharing.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Xin Cheng http://orcid.org/0000-0001-7816-0547
Dan Hong http://orcid.org/0000-0002-4002-4627
Xiaoyang Wu http://orcid.org/0000-0002-1332-6669
Qiu Gu http://orcid.org/0000-0003-2997-1788
Yang Li http://orcid.org/0000-0003-1009-2124
Yilong Wang http://orcid.org/0000-0002-3267-0039

REFERENCES


Downloaded from http://svn.bmj.com/ Stroke Vasc Neurol: first published as 10.1136/svn-2023-002820 on 29 January 2024. By guest. Protected by copyright.


